Effects of cyclosporin A and itraconazole on the pharmacokinetics of atorvastatin in rats

被引:16
作者
Dong, Jing [1 ]
Yu, Xue [1 ]
Wang, Lei [1 ]
Sun, Ye-bin [1 ]
Chen, Xi-jing [1 ]
Wang, Guang-ji [1 ]
机构
[1] China Pharmaceut Univ, Ctr Drug Metab & Pharmacokinet, Nanjing 210009, Peoples R China
基金
中国国家自然科学基金;
关键词
pharamcokinetics; P-glycoprotein; cytochrome P450 (CYP) 3A4; cyclosporin A; itraconazole; atorvastatin;
D O I
10.1111/j.1745-7254.2008.00858.x
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Aim: To evaluate the effects of cyclosporin A and itraconazole, which were used as inhibitors of P-glycoprotein (P-gp) and/or cytochrome P450 (CYP) 3A4 on the pharmacokinetics of atorvastatin in rats. Methods: The pharmacokinetic parameters of atorvastatin were measured after intravenous (2 mg/kg) and intra-gastric (10 mg/kg) administration of atorvastatin in rats, which were pretreated with cyclosporin A (5, 10, and 20 mg/kg) or itraconazole (5, 10, and 20 mg/kg). Results: Compared with the control rats, cyclosporin A and itraconazole altered the pharmacokinetics of atorvastatin significantly. The AUC(0-t) values of atorvastatin after intragastric administration, pretreated with cyclosporin A (5-20 mg/kg), increased by 32.3%, 61.8%, and 187.2%, respectively, but the CLbile values decreased (P < 0.01, 5-20 mg/kg). With pretreatment of itraconazole (5-20 mg/kg), the AUC(0-t) values of atorvastatin increased by 88.2%, 102%, and 123%, respectively, but the CLbile values decreased (P < 0.01, 5-20 mg/kg). Conclusion: These data indicated that cyclosporin A could be effective in inhibiting the efflux of atorvastatin, and itraconazole could be effective in inhibiting both the metabolism and biliary excretion of atorvastatin.
引用
收藏
页码:1247 / 1252
页数:6
相关论文
共 28 条
[1]  
Berruet N, 2005, J PHARM PHARM SCI, V8, P226
[2]  
Black AE, 1998, DRUG METAB DISPOS, V26, P755
[3]   Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition [J].
Dresser, GK ;
Spence, JD ;
Bailey, DG .
CLINICAL PHARMACOKINETICS, 2000, 38 (01) :41-57
[4]  
Gumprecht Janusz, 2003, Med Sci Monit, V9, pCS89
[5]   Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients [J].
Hermann, M ;
Åsberg, A ;
Christensen, H ;
Holdaas, H ;
Hartmann, A ;
Reubsaet, JLE .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (04) :388-391
[6]   Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins) [J].
Igel, M ;
Sudhop, T ;
vonBergmann, K .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (05) :357-364
[7]  
Ishigami M, 2001, DRUG METAB DISPOS, V29, P1068
[8]   Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors [J].
Jacobson, TA .
AMERICAN JOURNAL OF CARDIOLOGY, 2004, 94 (09) :1140-1146
[9]   In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats [J].
Kageyama, M ;
Namiki, H ;
Fukushima, H ;
Ito, Y ;
Shibata, N ;
Takada, K .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2005, 28 (02) :316-322
[10]   Effect of itraconazole on the pharmacokinetics of atorvastatin [J].
Kantola, T ;
Kivistö, KT ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (01) :58-65